<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372163</url>
  </required_header>
  <id_info>
    <org_study_id>B3301002</org_study_id>
    <nct_id>NCT01372163</nct_id>
  </id_info>
  <brief_title>A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients</brief_title>
  <official_title>A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Doses Of PF-05190457 In Healthy And Type 2 Diabetic Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after
      administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to
      evaluate the plasma drug concentrations after multiple doses.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    B3301002 was discontinued on 18 April 2012 for strategic reasons.There were no safety concerns
    leading to discontinuation of this study.
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a measure of safety and tolerability.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Area Under the Curve (AUC) and its accumulation ratio on days 1, 13, and 14, as appropriate and the data permit.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Maximum Concentration (Cmax) on days 1, 13, and 14, as appropriate and the data permit.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Time of Maximum concentration (Tmax) on days 1, 13, and 14, as appropriate and the data permit.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of the Minimum Amount of concentration (Cmin) on days 13 and 14, as appropriate and the data permit.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Elimination of half-life (t ½ ) on day 14, as the data permit.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of apparent total clearance of the drug from plasma after oral administration (CL/F) on days 13 and 14, as the data permit.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F) on days 13 and 14, as the data permit.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary recovery and renal clearance of PF-05190457 will be estimated via comparison of the plasma AUC and urinary excretion to provide AE0-τ, AE0-τ%, and CLR as the data permit.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>2 mg PF-05190457 or Placebo BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg PF-05190457 or Placebo BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg PF-05190457 or Placebo BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose and dose frequency may be adjusted based on emerging safety and PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg PF-05190457 or Placebo BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose and dose frequency may be adjusted based on emerging safety and PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg PF-05190457 or Placebo QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose and dose frequency may be adjusted based on emerging safety and PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg PF-05190457 or Placebo QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose and dose frequency may be adjusted based on emerging safety and PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>xxx mg PF-05190457 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose and dose frequency to be determined based on emerging safety and PK data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457 or Placebo</intervention_name>
    <description>Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.</description>
    <arm_group_label>2 mg PF-05190457 or Placebo BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457 or Placebo</intervention_name>
    <description>Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.</description>
    <arm_group_label>10 mg PF-05190457 or Placebo BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457 or Placebo</intervention_name>
    <description>Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.</description>
    <arm_group_label>40 mg PF-05190457 or Placebo BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457 or Placebo</intervention_name>
    <description>Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.</description>
    <arm_group_label>150 mg PF-05190457 or Placebo BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457 or Placebo</intervention_name>
    <description>Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.</description>
    <arm_group_label>5 mg PF-05190457 or Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457 or Placebo</intervention_name>
    <description>Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.</description>
    <arm_group_label>50 mg PF-05190457 or Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457 or Placebo</intervention_name>
    <description>Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.</description>
    <arm_group_label>xxx mg PF-05190457 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females of non-childbearing potential between ages of 18 and 55
             years, BMI of 18.5 to 30.5 kg/m^2, and weight between 50 and 100 kg, inclusive.

          -  Type 2 diabetic males and females of non-childbearing potential between ages of 18 and
             55 years, BMI of 18.5 to 40.0 kg/m^2, weight between 50 and 150 kg, and HbA1c of
             7.0-10.0%, inclusive.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease.

          -  Additionally, type 2 diabetic patients who have history of diabetic complications with
             significant end-organ damage or pharmacologic treatment for diabetes in addition to
             metformin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3301002&amp;StudyName=A%20Study%20Of%20PF-05190457%20In%20Healthy%20Volunteers%20And%20Type-2%20Diabetic%20Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Multiple Ascending Doses</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Type 2 Diabetic Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

